| http://www.w3.org/ns/prov#value | - This disorder is poorly understood, Professor Argos told the BMJ. It is underdiagnosed and undertreated.Professor Argos is an adviser to a small Australian biotechnology company, Healthtec, which is currently concluding phase II trials of indolebant, a cannabinoid CB1 receptor antagonist.
|
